{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:23:29Z","timestamp":1780561409397,"version":"3.54.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.berh.2023.101869","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T09:19:12Z","timestamp":1693387152000},"page":"101869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question"],"prefix":"10.1016","volume":"37","author":[{"given":"Zuzanna","family":"Lukasik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Carron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Webers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.berh.2023.101869_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101869_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20972610","article-title":"The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study","volume":"12","author":"Redeker","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"10.1016\/j.berh.2023.101869_bib5","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1093\/rheumatology\/keab887","article-title":"Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis","volume":"61","author":"De Craemer","year":"2022","journal-title":"Rheumatology"},{"issue":"Suppl4","key":"10.1016\/j.berh.2023.101869_bib6","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/rheumatology\/keaa435","article-title":"Treatment strategies in axial spondyloarthritis: what, when and how?","volume":"59","author":"Fragoulis","year":"2020","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2023.101869_bib7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/annrheumdis-2022-222324","article-title":"Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis","volume":"81","author":"Torgutalp","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101869_bib9","first-page":"CD004800","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"11","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.berh.2023.101869_bib10","first-page":"CD004524","article-title":"Methotrexate for ankylosing spondylitis","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.berh.2023.101869_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/BOR.0000000000000804","article-title":"Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?","volume":"33","author":"Sieper","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2023.101869_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/annrheumdis-2020-218304","article-title":"Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in\u00a0vivo","volume":"80","author":"Menegatti","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2023.101869_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FTD.0b013e3181cc6fef","article-title":"Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis","volume":"32","author":"Mulleman","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.berh.2023.101869_bib17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A\u00a0randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101869_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","article-title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve","volume":"74","author":"Pouw","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","article-title":"bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search","volume":"4","author":"Verhoef","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"7","key":"10.1016\/j.berh.2023.101869_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","article-title":"Ankylosing spondylitis: an autoimmune or autoinflammatory disease?","volume":"17","author":"Mauro","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2023.101869_bib21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","article-title":"Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study","volume":"76","author":"Carron","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2023.101869_bib22","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101869_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/hex.12046","article-title":"Burden of treatment for chronic illness: a concept analysis and review of the literature","volume":"18","author":"Sav","year":"2015","journal-title":"Health Expect"},{"issue":"2","key":"10.1016\/j.berh.2023.101869_bib24","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3899\/jrheum.150540","article-title":"Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort","volume":"43","author":"Greenberg","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2023.101869_bib26","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3899\/jrheum.100099","article-title":"Cost of illness from the public payers' perspective in patients with ankylosing spondylitis in rheumatological care","volume":"37","author":"Str\u00f6mbeck","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000230","article-title":"Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort","volume":"2","author":"Harvard","year":"2016","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.berh.2023.101869_bib28","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2023.101869_bib29","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","article-title":"Dosage adjustment of anti-tumor necrosis factor-\u03b1 inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice","volume":"39","author":"Paccou","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2023.101869_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2023.101869_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2023.101869_bib33","first-page":"2286","article-title":"A\u00a0new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2023.101869_bib34","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2023.101869_bib35","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","article-title":"Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial","volume":"41","author":"Song","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101869_bib36","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"issue":"7","key":"10.1016\/j.berh.2023.101869_bib37","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2023.101869_bib38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0394632016656013","article-title":"Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population","volume":"29","author":"Li","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2023.101869_bib40","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101869_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20929441","article-title":"Disease activity guided stepwise tapering or discontinuation of rhTNFR:Fc, an etanercept biosimilar, in patients with ankylosing spondylitis: a prospective, randomized, open-label, multicentric study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.berh.2023.101869_bib42","series-title":"Annals of the rheumatic diseases","article-title":"Feasibility of progressive anti-tnf tapering in axial spondyloarthritis patients in low disease activity: results from the multicenter NON-inferiority prospective randomized controlled trial spacing","year":"2021"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13063-019-4000-5","article-title":"Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial","volume":"21","author":"Michielsens","year":"2020","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.berh.2023.101869_bib44","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","article-title":"Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial","volume":"81","author":"Michielsens","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2023.101869_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","volume":"52","author":"Ruwaard","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2023.101869_bib46","series-title":"Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)","author":"Weinstein","year":"2023"},{"issue":"7","key":"10.1016\/j.berh.2023.101869_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028517","volume":"9","author":"Uhrenholt","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.berh.2023.101869_bib48","first-page":"1","article-title":"Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial","author":"Uhrenholt","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2023.101869_bib49","first-page":"1","article-title":"Predicting successful biologics tapering in patients with inflammatory arthritis: secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial","author":"Uhrenholt","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.berh.2023.101869_bib50","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.berh.2023.101869_bib51","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2023.101869_bib52","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.38014","article-title":"Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare","volume":"65","author":"Haibel","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-019-1943-6","article-title":"Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101869_bib55","series-title":"POS0942 development of prediction model for flare after tapering of TNF inhibitors in patients with axial spondyloarthritis","year":"2022"},{"issue":"2","key":"10.1016\/j.berh.2023.101869_bib56","doi-asserted-by":"crossref","first-page":"rkaa015","DOI":"10.1093\/rap\/rkaa015","article-title":"Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study","volume":"4","author":"Van Rossen","year":"2020","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"10.1016\/j.berh.2023.101869_bib57","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/rheumatology\/keab741","article-title":"Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study","volume":"61","author":"Michielsens","year":"2022","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2023.101869_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105358","article-title":"Factors associated with drug-free remission at 5-year in early onset axial spondyloarthritis patients: data from the DESIR cohort","volume":"89","author":"Ruyssen-Witrand","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90442-w","article-title":"Clinical factors associated with discontinuation of ts\/bDMARDs in rheumatic patients from the BIOBADASER III registry","volume":"11","author":"Prior-Espa\u00f1ol","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-020-02188-x","article-title":"Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis","volume":"22","author":"Vinson","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.berh.2023.101869_bib61","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1093\/rheumatology\/keab902","article-title":"Risk of flare after tapering or withdrawal of biologic\/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis","volume":"61","author":"Uhrenholt","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001136","article-title":"Peripheral spondyloarthritis: a neglected entity-state of the art","volume":"6","author":"Carron","year":"2020","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.berh.2023.101869_bib64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2023.101869_bib65","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2023.101869_bib66","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2004.031286","article-title":"Autoantibodies in biological agent naive patients with psoriatic arthritis","volume":"64","author":"Johnson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101869_bib67","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2018.01936","article-title":"Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA","volume":"9","author":"Frasca","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib68","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.berh.2023.101869_bib69","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2023.101869_bib70","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/annrheumdis-2013-203327","article-title":"Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2023.101869_bib71","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/art.40573","article-title":"High rate of drug-free remission after induction therapy with golimumab in early peripheral spondyloarthritis","volume":"70","author":"Carron","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2023.101869_bib73","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1093\/rheumatology\/keab873","article-title":"Cluster analysis in early axial spondyloarthritis predicts poor outcome in the presence of peripheral articular manifestations","volume":"61","author":"Costantino","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2023.101869_bib74","first-page":"63","article-title":"Dose reduction of biologic therapy in inflammatory arthritis: a qualitative study of patients' perceptions and needs","volume":"17","author":"Hewlett","year":"2019","journal-title":"Muscoskel Care"},{"issue":"3","key":"10.1016\/j.berh.2023.101869_bib75","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/03009742.2018.1533034","article-title":"Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think?","volume":"48","author":"Wallis","year":"2019","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2023.101869_bib76","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","article-title":"Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101869_bib77","series-title":"AB0958 a study on early tapering of tofacitinib in ankylosing spondylitis: a hit and run strategy","first-page":"1697","author":"Viswanath","year":"2023"},{"issue":"6","key":"10.1016\/j.berh.2023.101869_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105603","article-title":"Looking through the window of opportunity in axial spondyloarthritis?","volume":"90","author":"Benavent","year":"2023","journal-title":"Joint Bone Spine"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:24:20Z","timestamp":1761499460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1521694223000554"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101869","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101869"}}